Literature DB >> 27613260

Esophageal Motor Abnormalities in Patients With Scleroderma: Heterogeneity, Risk Factors, and Effects on Quality of Life.

Michael D Crowell1, Sarah B Umar2, W Leroy Griffing3, John K DiBaise2, Brian E Lacy4, Marcelo F Vela2.   

Abstract

BACKGROUND & AIMS: Systemic scleroderma (SSc) is associated with esophageal aperistalsis and hypotensive esophagogastric junction pressure, although there could be a gradation in esophageal motor dysfunction. We characterized esophageal motor function by high-resolution esophageal manometry (HRM) and assessed associations between SSc severity, health-related quality of life (HRQOL), and HRM findings in patients.
METHODS: We performed a prospective study of 200 patients with SSc and 102 patients without SSc (controls) who underwent HRM at Mayo Clinic Arizona from May 2006 through January 2015. We used data on integrated relaxation pressure, distal contractile integral, and distal latency to classify esophageal motility disorders according to the Chicago Classification v 3.0. A subset of subjects (n = 122) completed SSc-specific gastrointestinal symptom and HRQOL questionnaires. HRM findings, symptoms, and HRQOL data were compared among diffuse SSc, limited SSc, and control subjects. Categorical variables were compared by using the χ2 or Fisher exact test; continuous variables were compared by using Mann-Whitney or Kruskal-Wallis test. Multivariable logistic regression was used to assess the association between severity of esophageal dysmotility and baseline clinical factors.
RESULTS: Among patients with SSc, 83 had diffuse SSc (42%), and 117 had limited SSc (58%). Absent contractility was more frequent in patients with SSc than in controls (56% vs 13%; P < .001). HRM findings varied among the patients; absent contractility (56%) was the most frequent diagnosis, followed by normal motility (26%) and ineffective esophageal motility (10%). Classic scleroderma esophagus (esophagogastric junction pressure with absent contractility) was only observed in 33% of patients (34% with diffuse SSc vs 32% limited SSc) (P = .880). Severe esophageal dysmotility was associated with disease duration, interstitial lung disease, and higher gastrointestinal symptom scores (P < .001). HRQOL was decreased in patients with SSc and severe esophageal dysmotility.
CONCLUSIONS: Although severe dysmotility is more common in patients with SSc than in controls, we observed the so-called scleroderma esophagus in only one-third of patients with SSc. Esophageal motor function appears to be heterogeneous in SSc. Esophageal dysmotility reduces HRQOL in patients with SSc.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune Disorder; Dysphagia; High-resolution Esophageal Manometry; Reflux

Mesh:

Year:  2016        PMID: 27613260     DOI: 10.1016/j.cgh.2016.08.034

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  14 in total

1.  Relationship between esophageal motility abnormalities and skin or lung involvements in patients with systemic sclerosis.

Authors:  Shiko Kuribayashi; Sei-Ichiro Motegi; Kenichiro Hara; Yasuyuki Shimoyama; Hiroko Hosaka; Akiko Sekiguchi; Kouichi Yamaguchi; Osamu Kawamura; Takeshi Hisada; Osamu Ishikawa; Motoyasu Kusano; Toshio Uraoka
Journal:  J Gastroenterol       Date:  2019-04-01       Impact factor: 7.527

Review 2.  The Role of Impedance Planimetry in the Evaluation of Esophageal Disorders.

Authors:  Nitin K Ahuja; John O Clarke
Journal:  Curr Gastroenterol Rep       Date:  2017-02

Review 3.  The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review.

Authors:  Wouter Schutyser; Ludovic Cruyt; Jean-Baptiste Vulsteke; Jan L Lenaerts; Ellen De Langhe
Journal:  Clin Rheumatol       Date:  2019-11-11       Impact factor: 2.980

Review 4.  Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.

Authors:  S Kumar; J Singh; S Rattan; A J DiMarino; S Cohen; S A Jimenez
Journal:  Aliment Pharmacol Ther       Date:  2017-02-09       Impact factor: 8.171

5.  Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.

Authors:  Serena Vettori; Salvatore Tolone; Domenico Capocotta; Rossella Chieffo; Veronica Giacco; Gabriele Valentini; Ludovico Docimo
Journal:  Clin Rheumatol       Date:  2018-02-13       Impact factor: 2.980

6.  Individuals With Scleroderma May Have Increased Risk of Sleep-Disordered Breathing.

Authors:  Brandon T Nokes; Hassan A Raza; Rodrigo Cartin-Ceba; Phillip J Lyng; Lois E Krahn; Lewis Wesselius; Clinton E Jokerst; Sarah B Umar; W Leroy Griffing; Matthew R Neville; Atul Malhotra; James M Parish
Journal:  J Clin Sleep Med       Date:  2019-11-15       Impact factor: 4.062

7.  Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients.

Authors:  E K Stern; D A Carlson; S Falmagne; A D Hoffmann; M Carns; J E Pandolfino; M Hinchcliff; D M Brenner
Journal:  Neurogastroenterol Motil       Date:  2017-11-06       Impact factor: 3.598

Review 8.  GI Manifestations With a Focus on the Esophagus: Recent Progress in Understanding Pathogenesis.

Authors:  Marie-Pier Tétreault; Peter Kahrilas
Journal:  Curr Rheumatol Rep       Date:  2019-07-03       Impact factor: 4.592

9.  Esophageal Dilatation as a Predictor of Systemic Sclerosis in Patients with Interstitial Lung Disease.

Authors:  Ana Filipa Santos Duarte de Figueiredo; João Felício Costa; António P Matos; Miguel Ramalho
Journal:  Turk Thorac J       Date:  2021-05

Review 10.  Esophageal manifestation in patients with scleroderma.

Authors:  Theodoros A Voulgaris; Georgios P Karamanolis
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.